P-CD19CD20-ALLO1

· Genentech, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for P-CD19CD20-ALLO1, covering 2026-04-21 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) [Phase 1]

See pricing